Target intelligence / Profile preview

Hepatocyte nuclear factor 1-beta (HNF1B)

Target
HNF1B
Molecular classification
Transcription factor, Homeodomain protein, DNA-binding protein
01

Overview

Hepatocyte nuclear factor 1-beta (HNF1B) is a transcription factor in the homeodomain-containing protein family, essential for the regulation of gene expression in multiple organs including the kidneys, pancreas, liver, and urinary and genital tracts[2][3][4][6]. HNF1B binds DNA as a homodimer or heterodimer and regulates genes crucial to organ development and function[2][3][4]. Mutations in HNF1B are associated with autosomal dominant monogenic diabetes (MODY5), renal cysts and diabetes syndrome (RCAD), and congenital kidney/urinary tract anomalies (CAKUT)[3][4]. Besides its developmental roles, HNF1B dysfunction can alter insulin secretion and nephron development, and has been linked to certain cancers, e.g. prostate cancer[3]. As a transcription factor, it is not directly targeted by current medicines, but its mutation status is an important biomarker for clinical diagnosis, genetic counseling, and patient management in related syndromes[3][4].

Other names
HNF1 homeobox BHNF-1-betaHNF-1BTCF2TCF-2transcription factor 2MODY5VHNF1LFB3HNF1 beta Ahomeoprotein LFB3HPC11LF-B3RCADFJHN
02

Mechanism of action

Not a direct drug target; gene mutations affect regulatory pathways for insulin and renal function

03

Biological functions

Regulation of gene expressionOrgan development (kidney, pancreas, liver, urinary and genital tracts)Beta-cell function and insulin secretionEmbryogenesisCell differentiation
04

Disease associations

Monogenic diabetes (MODY5)Renal cysts and diabetes syndrome (RCAD)Congenital anomalies of kidney and urinary tract (CAKUT)17q12 deletion syndromeProstate cancerOther developmental disorders
05

Safety considerations

Difficulties in direct pharmacological targetingHeterogeneous clinical phenotypesMultisystem involvementGenetic testing and counseling complexity
06

Interacting drugs

None specifically approved; may be modulated indirectly (e.g., by antidiabetic therapy in MODY5 patients)
07

Biomarkers

HNF1B gene mutations (for MODY5, RCAD, CAKUT)17q12 microdeletionCysts in kidneys/liverEarly-onset diabetes with kidney disease

Beyond the preview

Go deeper on Hepatocyte nuclear factor 1-beta (HNF1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatocyte nuclear factor 1-beta (HNF1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call